Agenus Inc. (NASDAQ:AGEN)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a research note issued on Thursday.
The analysts wrote, “Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33).””
In related news, CEO Garo H. Armen purchased 100,000 shares of the stock in a transaction that occurred on Monday, May 9th. The stock was acquired at an average price of $3.18 per share, with a total value of $318,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,346,026 shares in the company, valued at approximately $4,280,362.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. Analysts anticipate that Agenus will post ($1.36) EPS for the current fiscal year.
Other hedge funds recently modified their holdings of the company. venBio Select Advisor LLC raised its stake in shares of Agenus by 9.2% in the first quarter. venBio Select Advisor LLC now owns 2,400,868 shares of the company’s stock worth $9,988,000 after buying an additional 201,731 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Agenus by 1.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,778,629 shares of the company’s stock worth $7,399,000 after buying an additional 17,006 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Agenus by 19.1% in the first quarter. Squarepoint Ops LLC now owns 76,700 shares of the company’s stock worth $319,000 after buying an additional 12,300 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Agenus by 167.9% in the first quarter. Goldman Sachs Group Inc. now owns 49,483 shares of the company’s stock worth $206,000 after buying an additional 31,014 shares in the last quarter. Finally, RTW Investments LLC raised its stake in shares of Agenus by 11.1% in the first quarter. RTW Investments LLC now owns 2,414,524 shares of the company’s stock worth $10,044,000 after buying an additional 241,257 shares in the last quarter.
A number of other research firms have also recently issued reports on AGEN. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research note on Saturday, April 30th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.39.
Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).
